{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:22:15Z","timestamp":1776406935723,"version":"3.51.2"},"reference-count":50,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Background\/Objectives: Obesity pharmacotherapy vastly improved the treatment of the disease of obesity. However, GLP-1 receptor agonists and GIP\/GLP-1 dual agonists may lead to nutritional complications, including severe caloric restriction, micronutrient deficiencies, lean body mass loss, dehydration, and ketosis. We examine these risks and outlines dietitian-led strategies to support improved safety and effectiveness. Methods: This narrative review was conducted in three stages: literature search, screening of abstracts and full texts, and synthesis of findings. Searches were carried out in April and May 2025 across PubMed, Embase, Scopus, ScienceDirect, Web of Science, and Google Scholar using keywords related to obesity pharmacotherapy and nutrition. Results: Clinical observations and trial data suggest that some individuals may consume fewer than 800 kcal\/day during the initial stages of treatment. Prolonged energy and protein deficits can increase the risk of sarcopenia, metabolic dysfunction, and reduce treatment adherence. Additional risks include inadequate micronutrient intake due to reduced dietary variety, dehydration linked to gastrointestinal symptoms and hypodipsia, and rare but serious cases of ketoacidosis. Patients at heightened risk include older adults, those with low baseline muscle mass, and individuals with restrictive eating patterns. Conclusions: Obesity medications introduce unique nutritional risks that are not yet addressed by standardised clinical protocols. Registered dietitians play a critical role in assessing intake patterns, monitoring for red flags, and delivering targeted nutritional support. Integrating structured dietary assessment tools, checklists, and risk-specific guidance into pharmacotherapy pathways can enhance safety, promote adherence, and improve long-term outcomes.<\/jats:p>","DOI":"10.3390\/nu17111934","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T03:58:52Z","timestamp":1749095932000},"page":"1934","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0020-4391","authenticated-orcid":false,"given":"Werd","family":"Al-Najim","sequence":"first","affiliation":[{"name":"Diabetes Complications Research Centre, School of Medicine, Conway Institute, University College Dublin, D04 V1W8 Dublin, Ireland"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5286-2249","authenticated-orcid":false,"given":"Ant\u00f3nio","family":"Raposo","sequence":"additional","affiliation":[{"name":"CBIOS (Research Center for Biosciences and Health Technologies), Universidade Lus\u00f3fona de Humanidades e Tecnologias, Campo Grande 376, 1749-024 Lisboa, Portugal"}]},{"given":"Mona N.","family":"BinMowyna","sequence":"additional","affiliation":[{"name":"College of Education, Shaqra University, Shaqra 11911, Saudi Arabia"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5521-5445","authenticated-orcid":false,"given":"Carel W.","family":"le Roux","sequence":"additional","affiliation":[{"name":"Diabetes Complications Research Centre, School of Medicine, Conway Institute, University College Dublin, D04 V1W8 Dublin, Ireland"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"The GBD 2015 Obesity Collaborators (2017). Health effects of overweight and obesity in 195 countries over 25 years. N. Engl. J. Med., 377, 13\u201327.","DOI":"10.1056\/NEJMoa1614362"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e65174","DOI":"10.1371\/journal.pone.0065174","article-title":"The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: A pooled analysis","volume":"8","author":"Singh","year":"2013","journal-title":"PLoS ONE"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Emerging Risk Factors Collaboration (2011). Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: Collaborative analysis of 58 prospective studies. Lancet, 377, 1085\u20131095.","DOI":"10.1016\/S0140-6736(11)60105-0"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer\u2014Viewpoint of the IARC Working Group","volume":"375","author":"Scoccianti","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jbspin.2010.04.011","article-title":"The relationship between body mass index and hip osteoarthritis: A systematic review and meta-analysis","volume":"78","author":"Jiang","year":"2011","journal-title":"Jt. Bone Spine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jbspin.2011.05.015","article-title":"Body mass index and susceptibility to knee osteoarthritis: A systematic review and meta-analysis","volume":"79","author":"Jiang","year":"2012","journal-title":"Jt. Bone Spine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1037\/amp0000517","article-title":"Lifestyle modification approaches for the treatment of obesity in adults","volume":"75","author":"Wadden","year":"2020","journal-title":"Am. Psychol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"101882","DOI":"10.1016\/j.eclinm.2023.101882","article-title":"Pharmacotherapy of obesity: An update on the available medications and drugs under investigation","volume":"58","author":"Chakhtoura","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.12998\/wjcc.v11.i19.4504","article-title":"Long-term effectiveness, outcomes and complications of bariatric surgery","volume":"11","author":"Gulinac","year":"2023","journal-title":"World J. Clin. Cases"},{"key":"ref_10","unstructured":"NICE (2025). Obesity: Identification, Assessment and Management, NICE."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Flore, G., Deledda, A., Fosci, M., Lombardo, M., Moroni, E., Pintus, S., Velluzzi, F., and Fantola, G. (2023). Perioperative Nutritional Management in Enhanced Recovery after Bariatric Surgery. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20196899"},{"key":"ref_12","first-page":"11","article-title":"Long-term complications of significant weight loss: Lessons learned from bariatric surgery","volume":"4","author":"Harrington","year":"2024","journal-title":"Metab. Target Organ Damage"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Astrup","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_16","first-page":"386","article-title":"GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment","volume":"23","author":"Mahase","year":"2024","journal-title":"BMJ"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b7 4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100121","DOI":"10.1016\/j.obpill.2024.100121","article-title":"Dietary intake by patients taking GLP-1 and dual GIP\/GLP-1 receptor agonists: A narrative review and discussion of research needs","volume":"11","author":"Christensen","year":"2024","journal-title":"Obes. Pillars."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cmet.2025.03.011","article-title":"Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation","volume":"35","author":"Ravussin","year":"2025","journal-title":"Cell Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 receptor agonist-induced weight loss: A review of central and peripheral pathways in appetite and energy regulation","volume":"138","author":"Moiz","year":"2025","journal-title":"Am. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12967-021-03221-6","article-title":"VLCKD: A real time safety study in obesity","volume":"20","author":"Barrea","year":"2022","journal-title":"J. Transl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e2457349","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.mcna.2017.08.007","article-title":"Addressing obesity in aging patients","volume":"102","author":"Batsis","year":"2017","journal-title":"Med. Clin. N. Am."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/eat.24109","article-title":"Use of glucagon-like peptide-1 receptor agonists in eating disorder populations","volume":"57","author":"Bartel","year":"2024","journal-title":"Int. J. Eat. Disord."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1177\/0148607114550189","article-title":"Lean tissue imaging: A new era for nutritional assessment and intervention","volume":"38","author":"Prado","year":"2014","journal-title":"J. Parenter. Enter. Nutr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.clnu.2014.04.007","article-title":"Protein intake and exercise for optimal muscle function with aging: Recommendations from the ESPEN Expert Group","volume":"33","author":"Deutz","year":"2014","journal-title":"Clin. Nutr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/obr.12143","article-title":"Weight loss composition is one-fourth fat-free mass: A critical review and critique of this widely cited rule","volume":"15","author":"Heymsfield","year":"2014","journal-title":"Obes. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00125-019-05065-8","article-title":"Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: A substudy of the SUSTAIN 8 randomised controlled clinical trial","volume":"63","author":"McCrimmon","year":"2020","journal-title":"Diabetologia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1111\/dom.15113","article-title":"Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes","volume":"25","author":"Silver","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: Revised European consensus on definition and diagnosis","volume":"48","author":"Bahat","year":"2019","journal-title":"Age Ageing"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1007\/s00198-016-3617-4","article-title":"The effects of weight loss approaches on bone mineral density in adults: A systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"Soltani","year":"2016","journal-title":"Osteoporos. Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1002\/jbmr.2564","article-title":"Does diet-induced weight loss lead to bone loss in overweight or obese adults? A systematic review and meta-analysis of clinical trials","volume":"30","author":"Zibellini","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/obr.12250","article-title":"Pathways from dieting to weight regain, to obesity and to the metabolic syndrome: An overview","volume":"16","author":"Dulloo","year":"2015","journal-title":"Obes. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.clnu.2012.06.010","article-title":"Sarcopenic obesity: A critical appraisal of the current evidence","volume":"31","author":"Prado","year":"2012","journal-title":"Clin. Nutr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/CIRCULATIONAHA.124.072679","article-title":"Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity","volume":"151","author":"Zile","year":"2025","journal-title":"Circulation"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1566498","DOI":"10.3389\/fnut.2025.1566498","article-title":"Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: A cross-sectional study","volume":"12","author":"Johnson","year":"2025","journal-title":"Front. Nutr."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11695-015-1773-9","article-title":"Micronutrient deficiencies in morbidly obese women prior to bariatric surgery","volume":"26","author":"Rojas","year":"2016","journal-title":"Obes. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.soard.2013.10.003","article-title":"Nutrient deficiencies in patients with obesity considering bariatric surgery: A cross-sectional study","volume":"10","author":"Lefebvre","year":"2014","journal-title":"Surg. Obes. Relat. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1007\/s11695-011-0360-y","article-title":"Nutritional intake and prevalence of nutritional deficiencies prior to surgery in a Spanish morbidly obese population","volume":"21","author":"Deulofeu","year":"2011","journal-title":"Obes. Surg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1416985","DOI":"10.3389\/fphar.2024.1416985","article-title":"Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events","volume":"15","author":"He","year":"2024","journal-title":"Front. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"R1755","DOI":"10.1152\/ajpregu.00472.2011","article-title":"Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake","volume":"301","author":"McKay","year":"2011","journal-title":"Am. J. Physiol.-Regul. Integr. Comp. Physiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"16417","DOI":"10.1523\/JNEUROSCI.3267-14.2014","article-title":"Endogenous glucagon-like peptide-1 reduces drinking behavior and is differentially engaged by water and food intakes in rats","volume":"34","author":"McKay","year":"2014","journal-title":"J. Neurosci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2015","journal-title":"Rev. Diabet. Stud. RDS"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12020-020-02394-2","article-title":"Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers","volume":"70","author":"Winzeler","year":"2020","journal-title":"Endocrine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1210\/clinem\/dgad471","article-title":"Glucagon-like peptide 1 analogues as adjunctive therapy for patients with type 1 diabetes: An updated systematic review and meta-analysis","volume":"109","author":"Park","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.numecd.2021.10.003","article-title":"The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system","volume":"32","author":"Yang","year":"2022","journal-title":"Nutr. Metab. Cardiovasc. Dis."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/17\/11\/1934\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:46:49Z","timestamp":1760032009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/17\/11\/1934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["nu17111934"],"URL":"https:\/\/doi.org\/10.3390\/nu17111934","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]}}}